Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma.

Authors

• Hsiang-Chi Tseng
• Wei Xiong
• Saiaditya Badeti
• Yan Yang
• Minh Ma
• Ting Liu
• Carlos A Ramos
• Gianpietro Dotti
• Luke Fritzky
• Jie-Gen Jiang
• Qing Yi
• James Guarrera
• Wei-Xing Zong
• Chen Liu
• Dongfang Liu

Publication/Presentation Date

9-23-2020

Abstract

Chimeric antigen receptor (CAR) therapy is a promising immunotherapeutic strategy for treating multiple refractory blood cancers, but further advances are required for solid tumor CAR therapy. One challenge is identifying a safe and effective tumor antigen. Here, we devise a strategy for targeting hepatocellular carcinoma (HCC, one of the deadliest malignancies). We report that T and NK cells transduced with a CAR that recognizes the surface marker, CD147, also known as Basigin, can effectively kill various malignant HCC cell lines in vitro, and HCC tumors in xenograft and patient-derived xenograft mouse models. To minimize any on-target/off-tumor toxicity, we use logic-gated (log) GPC3-synNotch-inducible CD147-CAR to target HCC. LogCD147-CAR selectively kills dual antigen (GPC3

Volume

11

Issue

1

First Page

4810

Last Page

4810

ISSN

2041-1723

Published In/Presented At

Tseng, H. C., Xiong, W., Badeti, S., Yang, Y., Ma, M., Liu, T., Ramos, C. A., Dotti, G., Fritzky, L., Jiang, J. G., Yi, Q., Guarrera, J., Zong, W. X., Liu, C., & Liu, D. (2020). Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nature communications, 11(1), 4810. https://doi.org/10.1038/s41467-020-18444-2

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

32968061

Department(s)

Administration and Leadership

Document Type

Article